Drug Trial Radar · NCT01898364
Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients.
Last checked: Nov 20, 2026Latest source record: Mar 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Aug 19, 2013
Primary completion
Feb 25, 2015
Study completion Feb 25, 2015
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jul 12, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: To evaluate the safety and tolerability of neoGAA in treatment naïve and alglucosidase alfa treated late-onset Pompe disease patients. Secondary Objective: To evaluate the pharmacokinetics, pharmacodynamics of neoGAA in treatment naïve and alglucosidase alfa treated late-onset Pompe disease patients. To evaluate the effect of neoGAA on exploratory efficacy endpoints in treatment naïve and alglucosidase alfa treated late-onset Pompe disease patients.
Conditions
- Pompe Disease
- Glycogen Storage Disease Type II (GSD II)
- Acid Maltase Deficiency
Interventions
GZ402666Drug
Pharmaceutical form:lyophilized powder reconstituted for infusion Route of administration: intravenous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse eventsTime frame: screening/baseline to Week 25
- Laboratory assessments including hematology, biochemistry and urinalysisTime frame: screening/baseline to Week 25
- Vital signsTime frame: screening/baseline to Week 25
Locations
17 sites in 7 countries. Site status is shown where the registry gives one.
Investigational Site Number 840006
Phoenix, Arizona
Investigational Site Number 840010
Jacksonville, Florida
Investigational Site Number 840001
Kansas City, Kansas
Investigational Site Number 840008
St Louis, Missouri
Investigational Site Number 840002
Durham, North Carolina
Investigational Site Number 840009
Dallas, Texas
Investigational Site Number 840003
Fairfax, Virginia
Investigational Site Number 056001
Leuven, Belgium
Investigational Site Number 208001
København Ø, Denmark
Investigational Site Number 250001
Marseille, France
Investigational Site Number 250003
Nice, France
Investigational Site Number 250002
Paris, France
Investigational Site Number 276003
Mainz, Germany
Investigational Site Number 276001
München, Germany
Investigational Site Number 276002
Münster, Germany
Investigational Site Number 528001
Rotterdam, Netherlands
Investigational Site Number 826003
Newcastle upon Tyne, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.